Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • (Business Wire India); Teva Pharmaceutical Industries Ltd. has announced that an updated investor presentation in connection with its proposed combination with Mylan N.V. is available on the Investor Relations section of the Company’s website and will be filed with the Securities and Exchange Commission (“SEC”).

  • Breast cancer vaccines and silicon microparticles together may work better

    The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).

  • The European Commission has granted marketing authorization in Europe for Sanofi's Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults. Its significant milestone for Sanofi. This gives people with diabetes and their physicians a new option to manage their condition.

  • aTyr Pharma, a biotherapeutics company engaged in the discovery and development of physiocrine-based therapeutics to address rare diseases, announced  that Resolaris has been granted Orphan Drug designation by the US Food and Drug Administration (FDA) for the treatment of facioscapulohumeral muscular dystrophy (FSHD).  Resolaris, an investigational new drug,  is being developed as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.

  • Women glow during pregnancy because they share the blood of their young foetus which has a rejuvenating effect on the mother which regenerates tissue and slow down the ageing process, according to a report. The oft-used phrase “pregnancy glow” seems to now have some basis in science because pregnancy helps regenerate tissue and slow down the ageing process. The effect occurs because of the shared blood between mother and child.

  • The government gave its approval for signing of an agreement with Mauritius on cooperation in traditional medicine systems and homoepathy. In a meeting, the Union cabinet chaired by Prime Minister Narendra Modi gave its approval for the memorandum of understanding between the two countries to enhance bilateral cooperation in areas of traditional medicine including medicinal plants, Telecom Minister Ravi Shankar Prasad said told reporters.

  • Three Indian pharmaceutical companies, namely Alembic Pharmaceuticals, Hetero Labs and Torrent Pharmaceuticals have get the US Food and Drug Administration (FDA) approval for generic versions of Abilify (aripiprazole). Aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.   Teva Pharmaceuticals has also get  similar approval.

     

    [adsense:336x280:8701650588]

  • Last week 7.8 magnitude earthquake hit Nepal. In response to this Novo Nordisk India has shared  donation of  75,000 insulin vials to the Indian government’s relief operations. The insulin valued at Rs.1 crore. This is to support people with diabetes who have been affected by the earthquake and who currently need access to this life saving medication. As damage and destruction has made living in Nepal citizens, people with diabetes in Nepal are facing difficulty to get medications.

  • As dietary supplements may be advertised to promote health but according to a study conducted by University of Colorado, excessive use of over-the-counter vitamins and other dietary supplements may raise the risk of malignancies, The exact molecular mechanisms are unknown; however, the causal role of excessive dietary supplements and higher risk of developing cancer is well-established.

  • A fast-acting transdermal gel using a proprietary formulation of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen helps in reduced pain severity in patients with severe migraine with or without auracompared with placebo and had few adverse effects. The phase 2a trial results were presented at the American Academy of Neurology (AAN) 67th Annual Meeting. The study shows the pathogenesis of severe headaches that are due to neurogenic inflammation.  If proved in large-scale trials, it may be new era  in neurological practice and introduction of new topical treatment of migraine. Oral analgesics such as cyclooxygenase inhibitors reduce inflammation but cause undesirable gastrointestinal effects.

Subscribe to Pharma News